Johnson & Johnson Announces Leadership Changes in Finance

Johnson & Johnson has announced key leadership changes in its finance team, with Darren Snellgrove appointed as Vice President of Investor Relations and Jessica Moore stepping into the role of Group Chief Financial Officer for Johnson & Johnson Innovative Medicine. Effective May 1, 2025, both executives will continue reporting to CFO Joseph Wolk as they transition into their new responsibilities. These appointments highlight the company's commitment to developing internal talent and fostering leadership growth.

Snellgrove, a 25-year veteran of Johnson & Johnson, brings extensive experience across finance, R&D, and business development, having most recently served as Group CFO for Innovative Medicine. Meanwhile, Moore, who has led Investor Relations since 2021, will leverage her deep financial expertise to support the strategic direction of the company’s Innovative Medicine division. With these leadership shifts, Johnson & Johnson aims to strengthen its financial strategy and investor engagement, reinforcing its long-term growth vision.